Apr 25, 2026

Subject: Burnout isn’t stress. It’s executive function collapse.

Sender: newsletter@kevinmd.com

Discover why burnout is more than just stress—it’s a collapse of your brain’s executive function. Explore how this cognitive breakdown manifests and begin your journey to recovery.

Also in this edition:

– Handling painful physician negative feedback with self-compassion.

– Unveiling overlooked ADHD stimulant risks and safer alternatives.

– Moral injury recognized in DSM Z code: healing through connection and compassion.

– The irreplaceable role of empathy in healthcare beyond algorithms.

– Protecting doctors from harms of ambiguous CPT coding.

– Addressing crises in Philadelphia prisons through addiction medicine.

– Challenges facing primary care amid value-based reforms.

– The importance of youth bone health and osteoporosis prevention.

– Recognizing orthorexia nervosa beneath wellness trends.

– Reclaiming physician agency against corporate medicine’s moral injury.

Join thousands of physicians discovering new opportunities nationwide. Subscribe or share with a friend at KevinMD.

Subject: Trump ushers in new era of drug policies

Sender: newsletter@statnews.com

President Trump has shifted U.S. drug policy by reclassifying medical marijuana from Schedule I to Schedule III and expanding research access to psychedelics, signaling a new Republican stance on drug regulation.

Other highlights include:

– CMS and FDA fast-tracking Medicare coverage for breakthrough medical devices to address delays and improve innovation uptake.

– A study revealing that the heart’s constant mechanical stress may prevent cancer growth, explaining the rarity of cardiac cancers.

– Detailed coverage of Trump’s policy moves on psychedelics, with insights into implications for mental health treatments.

– Regeneron’s drug pricing deal with the administration and FDA approval of Otarmeni, a gene therapy for rare hearing loss.

– Global childhood immunization catch-up efforts vaccinating millions through the Big Catch-Up program.

Stay informed with the latest in drug policy, health tech, and global health initiatives with STAT.

Subject: 🤖 AI drug hypes

Sender: caitlin@axios.com

Welcome to the AI drug discovery era, where the potential is vast but current results fall short of the hype. Major tech and pharma companies are investing billions, partnering to accelerate drug R&D, yet fewer AI-discovered drugs have reached the market than expected.

Key insights:

– Merck, Amazon AWS, Novo Nordisk, OpenAI, Nvidia, and Eli Lilly are among those forging AI partnerships.

– Alex Zhavoronkov (Insilico Medicine) cautions against AI overhype but emphasizes transformative potential for faster and cost-effective drug discovery.

– AI-enabled medicine like Insilico’s rentosertib shows promise in targeting diseases such as idiopathic pulmonary fibrosis.

– Regulatory and clinical trial hurdles remain significant despite AI’s promise.

– The challenge of insurance denials for new branded medicines worsens, impacting patient access.

Understand the evolving landscape where AI tools accelerate discovery but human trials and validation remain essential.

Subject: Heart’s pumping motion seems to keep cancer at bay

Sender: briefing@nature.com

New research shows the mechanical action of the heart’s beating can inhibit tumor growth, which offers an explanation for the rarity of heart cancers across mammals.

Additional stories include:

– Fossil evidence suggesting giant kraken octopuses ruled ancient seas during the Cretaceous period.

– The National Science Library of China’s halt on its journal ranking and the resulting implications for research evaluation.

– Harvard graduate students striking for better wages and protections, spotlighting the academic labor landscape.

– Geopolitical factors affecting access to major health data sets like the UK Biobank, raising concerns about data equity and national security.

– Innovative AI-powered projects like the robotic table-tennis player “Ace” pushing technological limits.

Discover the latest in scientific advances, academic affairs, and global health data challenges.

Subject: One month to go: Breakthrough West’s full agenda is live

Sender: marketing@statnews.com

STAT Breakthrough Summit West is one month away! This year’s summit features the most AI-focused program yet, spotlighting how AI and emerging technologies are driving real medical breakthroughs.

Agenda highlights:

– In-depth conversations on AI’s role in accelerating drug development and improving patient care.

– Explorations into what follows AI adoption with platforms like OpenEvidence.

– Perspectives from leaders at BridgeBio, Insmed, 23andMe, and more.

Featured speakers:

– Ted W. Love, M.D., Immediate Past Chair, BIO

– Anne Wojcicki, CEO, 23andMe Research Institute

– Neil Kumar, CEO, BridgeBio Pharma

– Jacqueline Poot, President, Strategic Consulting and Analytics, IDEA Pharma

– Joe Betts-LaCroix, CEO, Retro Biosciences

– Zachary Ziegler, CTO, OpenEvidence

Limited passes available for the live event in San Francisco or online on May 19, 2026. Register today to join pioneers, researchers, and patients at the forefront of healthcare innovation.

Stay Well!